452 related articles for article (PubMed ID: 33968718)
1. MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.
Ghafouri-Fard S; Gholipour M; Taheri M
Front Oncol; 2021; 11():608987. PubMed ID: 33968718
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy.
Segura MF; Greenwald HS; Hanniford D; Osman I; Hernando E
Carcinogenesis; 2012 Oct; 33(10):1823-32. PubMed ID: 22693259
[TBL] [Abstract][Full Text] [Related]
3. [The genetic markers and targets of target therapy of melanoma.].
Mazurenko NN; Gulyaeva LF; Kushlinskii NE
Klin Lab Diagn; 2017; 62(6):363-371. PubMed ID: 31505115
[TBL] [Abstract][Full Text] [Related]
4. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
5. Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma.
Pejkova S; Dzokic G; Tudzarova-Gjorgova S; Panov S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016 Nov; 37(2-3):89-97. PubMed ID: 27883322
[TBL] [Abstract][Full Text] [Related]
6. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.
Gast A; Scherer D; Chen B; Bloethner S; Melchert S; Sucker A; Hemminki K; Schadendorf D; Kumar R
Genes Chromosomes Cancer; 2010 Aug; 49(8):733-45. PubMed ID: 20544847
[TBL] [Abstract][Full Text] [Related]
7. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
8. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
9. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in the pathogenesis of malignant melanoma.
Glud M; Gniadecki R
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):142-50. PubMed ID: 22621697
[TBL] [Abstract][Full Text] [Related]
11. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
12. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
13. The genome and epigenome of malignant melanoma.
Dahl C; Guldberg P
APMIS; 2007 Oct; 115(10):1161-76. PubMed ID: 18042149
[TBL] [Abstract][Full Text] [Related]
14. Identification of microRNA signature and potential pathway targets in prostate cancer.
Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
[TBL] [Abstract][Full Text] [Related]
15. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
Emran AA; Chinna Chowdary BR; Ahmed F; Hammerlindl H; Huefner A; Haass NK; Schuehly W; Schaider H
Cancer Med; 2019 Mar; 8(3):1186-1196. PubMed ID: 30793515
[TBL] [Abstract][Full Text] [Related]
16. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
17. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Tsao H; Goel V; Wu H; Yang G; Haluska FG
J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
[TBL] [Abstract][Full Text] [Related]
18. The Genetic Evolution of Melanoma from Precursor Lesions.
Shain AH; Yeh I; Kovalyshyn I; Sriharan A; Talevich E; Gagnon A; Dummer R; North J; Pincus L; Ruben B; Rickaby W; D'Arrigo C; Robson A; Bastian BC
N Engl J Med; 2015 Nov; 373(20):1926-36. PubMed ID: 26559571
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations in signaling pathways in melanoma.
Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049
[TBL] [Abstract][Full Text] [Related]
20. Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma.
Linck-Paulus L; Hellerbrand C; Bosserhoff AK; Dietrich P
Cells; 2020 Jan; 9(1):. PubMed ID: 31906510
[No Abstract] [Full Text] [Related]
[Next] [New Search]